Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Greenwich Lifesciences Inc (GLSI)

Greenwich Lifesciences Inc (GLSI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 183,383
  • Shares Outstanding, K 12,824
  • Annual Sales, $ 0 K
  • Annual Income, $ -4,570 K
  • 60-Month Beta 0.26
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 12.07
Trade GLSI with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.19
  • Number of Estimates 1
  • High Estimate -0.19
  • Low Estimate -0.19
  • Prior Year -0.18
  • Growth Rate Est. (year over year) -5.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.72 +58.72%
on 11/03/22
14.99 -7.67%
on 11/28/22
+4.52 (+48.50%)
since 10/28/22
3-Month
8.39 +64.96%
on 09/06/22
14.99 -7.67%
on 11/28/22
+4.69 (+51.26%)
since 08/29/22
52-Week
6.82 +102.81%
on 06/13/22
36.27 -61.84%
on 12/08/21
-19.26 (-58.19%)
since 11/26/21

Most Recent Stories

More News
Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences...

GLSI : 13.69 (-4.27%)
Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences...

GLSI : 13.69 (-4.27%)
Greenwich LifeSciences Provides Financing Strategy & Corporate Update

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences...

GLSI : 13.69 (-4.27%)
Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced that the Food and Drug Administration (FDA)...

GLSI : 13.69 (-4.27%)
Greenwich LifeSciences Announces Suspension of Share Repurchase Program

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced that its Board of Directors has suspended the...

GLSI : 13.69 (-4.27%)
Greenwich LifeSciences to Resume Stock Repurchase Program

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced today it would resume its existing Stock Repurchase...

GLSI : 13.69 (-4.27%)
Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences...

GLSI : 13.69 (-4.27%)
New 52-Week Low Could Prompt More Insider Buying At GLSI

In trading on Tuesday, shares of Greenwich LifeSciences Inc touched a new 52-week low of $14.33/share. That's a $34.63 share price drop, or -70.73% decline from the 52-week high of $48.96 set back on...

GLSI : 13.69 (-4.27%)
Greenwich LifeSciences Becomes Oversold (GLSI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

GLSI : 13.69 (-4.27%)
Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences...

GLSI : 13.69 (-4.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Greenwich LifeSciences Inc. is a clinical stage biopharmaceutical company focuses on the development of cancer immunotherapies for breast cancer and other human epidermal growth factor. The company's product candidate includes GP2, which is in clinical stage. Greenwich LifeSciences Inc.is based in Stafford,...

See More

Key Turning Points

3rd Resistance Point 16.50
2nd Resistance Point 15.75
1st Resistance Point 15.02
Last Price 13.69
1st Support Level 13.54
2nd Support Level 12.79
3rd Support Level 12.06

See More

52-Week High 36.27
Fibonacci 61.8% 25.02
Fibonacci 50% 21.55
Fibonacci 38.2% 18.07
Last Price 13.69
52-Week Low 6.82

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar